These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

546 related items for PubMed ID: 24595567

  • 21. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.
    Sandborn WJ, Ghosh S, Panes J, Vranic I, Wang W, Niezychowski W, Study A3921043 Investigators.
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1485-93.e2. PubMed ID: 24480677
    [Abstract] [Full Text] [Related]

  • 22. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
    Asahina A, Etoh T, Igarashi A, Imafuku S, Saeki H, Shibasaki Y, Tomochika Y, Toyoizumi S, Nagaoka M, Ohtsuki M, study investigators.
    J Dermatol; 2016 Aug; 43(8):869-80. PubMed ID: 26875540
    [Abstract] [Full Text] [Related]

  • 23. The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib.
    Bushmakin AG, Mamolo C, Cappelleri JC, Stewart M.
    J Dermatolog Treat; 2015 Feb; 26(1):19-22. PubMed ID: 24289224
    [Abstract] [Full Text] [Related]

  • 24. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
    Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C, ORAL Step investigators.
    Lancet; 2013 Feb 09; 381(9865):451-60. PubMed ID: 23294500
    [Abstract] [Full Text] [Related]

  • 25. Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.
    Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R.
    Br J Dermatol; 2019 Jan 09; 180(1):67-75. PubMed ID: 30188571
    [Abstract] [Full Text] [Related]

  • 26. Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design.
    Ports WC, Feldman SR, Gupta P, Tan H, Johnson TR, Bissonnette R.
    J Drugs Dermatol; 2015 Aug 09; 14(8):777-84. PubMed ID: 26267721
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
    Kuo CM, Tung TH, Wang SH, Chi CC.
    J Eur Acad Dermatol Venereol; 2018 Mar 09; 32(3):355-362. PubMed ID: 29136293
    [Abstract] [Full Text] [Related]

  • 28. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
    Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS.
    N Engl J Med; 2017 Oct 19; 377(16):1525-1536. PubMed ID: 29045207
    [Abstract] [Full Text] [Related]

  • 29. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
    Krueger J, Clark JD, Suárez-Fariñas M, Fuentes-Duculan J, Cueto I, Wang CQ, Tan H, Wolk R, Rottinghaus ST, Whitley MZ, Valdez H, von Schack D, O'Neil SP, Reddy PS, Tatulych S, A3921147 Study Investigators.
    J Allergy Clin Immunol; 2016 Apr 19; 137(4):1079-1090. PubMed ID: 27059729
    [Abstract] [Full Text] [Related]

  • 30. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
    Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R, Papp K.
    Br J Dermatol; 2013 Jul 19; 169(1):137-45. PubMed ID: 23387374
    [Abstract] [Full Text] [Related]

  • 31. Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.
    Fitz L, Zhang W, Soderstrom C, Fraser S, Lee J, Quazi A, Wolk R, Mebus CA, Valdez H, Berstein G.
    Clin Exp Dermatol; 2018 Oct 19; 43(7):790-797. PubMed ID: 29748971
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
    Cohen SB, Koenig A, Wang L, Kwok K, Mebus CA, Riese R, Fleischmann R.
    Clin Exp Rheumatol; 2016 Oct 19; 34(1):32-6. PubMed ID: 26575982
    [Abstract] [Full Text] [Related]

  • 33. Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study.
    Valenzuela F, Korman NJ, Bissonnette R, Bakos N, Tsai TF, Harper MK, Ports WC, Tan H, Tallman A, Valdez H, Gardner AC.
    Br J Dermatol; 2018 Oct 19; 179(4):853-862. PubMed ID: 29782642
    [Abstract] [Full Text] [Related]

  • 34. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
    Panés J, Su C, Bushmakin AG, Cappelleri JC, Mamolo C, Healey P.
    BMC Gastroenterol; 2015 Feb 05; 15():14. PubMed ID: 25651782
    [Abstract] [Full Text] [Related]

  • 35. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
    Fleischmann R, Mease PJ, Schwartzman S, Hwang LJ, Soma K, Connell CA, Takiya L, Bananis E.
    Clin Rheumatol; 2017 Jan 05; 36(1):15-24. PubMed ID: 27734232
    [Abstract] [Full Text] [Related]

  • 36. Emerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib.
    McAndrew R, Levin E, Koo J.
    J Drugs Dermatol; 2015 Aug 05; 14(8):786-92. PubMed ID: 26267722
    [Abstract] [Full Text] [Related]

  • 37. Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Tan H, Valdez H, Griffins CE, Mrowietz U, Tallman A, Wolk R, Gordon K.
    J Dermatolog Treat; 2017 Feb 05; 28(1):3-7. PubMed ID: 27538247
    [Abstract] [Full Text] [Related]

  • 38. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
    Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S, Wallenstein G, Wilkinson BE, Zwillich SH.
    Arthritis Rheum; 2012 Mar 05; 64(3):617-29. PubMed ID: 21952978
    [Abstract] [Full Text] [Related]

  • 39. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
    Berekmeri A, Mahmood F, Wittmann M, Helliwell P.
    Expert Rev Clin Immunol; 2018 Sep 05; 14(9):719-730. PubMed ID: 30118353
    [Abstract] [Full Text] [Related]

  • 40. Tofacitinib for the treatment of moderate-to-severe psoriasis.
    Chiricozzi A, Faleri S, Saraceno R, Bianchi L, Buonomo O, Chimenti S, Chimenti MS.
    Expert Rev Clin Immunol; 2015 Apr 05; 11(4):443-55. PubMed ID: 25666451
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.